Rapport Therapeutics, Inc. Common Stock Stock Prediction and Forecast [RAPP]
1 extracted signal · 1 resolved · 0 still active
StockInvest.usIndependent analyst profile- Source published
- 06 Sept 2025, 03:46 UTC
- Recorded by Tahlil Plus
- 18 May 2026, 20:23 UTC
![Video preview for Rapport Therapeutics, Inc. Common Stock Stock Prediction and Forecast [RAPP]](https://i.ytimg.com/vi/JBAhudfhIc4/hqdefault.jpg)
AI-generated source summary
The analysis focuses on Rapport Therapeutics, stock RAPP. Since September 5th, 2025, the system ranks RAPP as a sell candidate with a score of -4.563. A 3-month trend suggests a potential 34.71% change, with returns ranging from 34.71% to 68.18%. The 12-month analysis forecasts a negative change of -37.75%, varying from -94.88% to -17.62%. On Friday, September 5th, the stock closed at $14.36, down 6.45%. The stock fluctuated 12.32% during the day. A buy signal from the 3-month Moving Average Convergence Divergence (MACD) exists, negative signals are also present. RAPP holds sell signals from both short and long-term Moving Averages. Resistance levels are at $15.79 and $15.14. Insider trading shows recent sells, which may have early warning indicating that the stock should be followed more closely. RAPP finds support at $12.66 and $12.04. Stock's volume rose on falling prices on Friday.The general rating for RAPP is a sell
AI-generated summary based on the source content.
Signal outcomes at a glance
Evaluation CompleteSignals in this source
Evidence and evaluation progress
- Original source published
The analyst published the original source item.
- First prediction resolved
The first evaluable outcome in this case reached a terminal result.
- Case evaluation completed
All evaluable predictions in this case reached terminal outcomes.
- Source recorded by Tahlil Plus
The public source was preserved as the evidence record for this case.
- Market predictions extracted
1 eligible signal linked to this case.
- Outcome tracking started
Tahlil Plus began monitoring the extracted predictions.
StockInvest.us
Platform-wide history, separate from this source evaluation.
Tahlil Plus independently records and evaluates public market predictions. Extraction may be AI-assisted and results follow the Tahlil Plus methodology. This information is not financial advice.